No Data
No Data
PharmaTher's Sairiyo Therapeutics Gets OK to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
Express News | Pharmather Holdings Ltd - Generic Drug User Fee Amendments of 2022 Goal Date of October 29, 2024
Express News | Pharmather Holdings Ltd - Receipt of Amendment Acknowledgment Letter for Its Priority Original Abbreviated New Drug Application for Ketamine
Express News | Pharmather Holdings Ltd - Receipt of a Complete Response Letter ("Crl") for Its Priority Original Abbreviated New Drug Application for Ketamine
Express News | Pharmather Holdings Ltd: Has Completed Necessary Tests and Responses to Address Fda's Comments
PharmaTher Updated on Its Priority Original Abbreviated New Drug Application for Ketamine
No Data